Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003829862 | SCV004629045 | uncertain significance | Rubinstein-Taybi syndrome | 2023-06-15 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on CREBBP protein function. This variant has not been reported in the literature in individuals affected with CREBBP-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces proline, which is neutral and non-polar, with histidine, which is basic and polar, at codon 1648 of the CREBBP protein (p.Pro1648His). |
Ambry Genetics | RCV004981067 | SCV005562765 | uncertain significance | Inborn genetic diseases | 2024-09-11 | criteria provided, single submitter | clinical testing | The c.4943C>A (p.P1648H) alteration is located in exon 30 (coding exon 30) of the CREBBP gene. This alteration results from a C to A substitution at nucleotide position 4943, causing the proline (P) at amino acid position 1648 to be replaced by a histidine (H). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |